TOPAbout TaihoForeign Subsidiaries

Foreign Subsidiaries

Pursuing higher quality pharmaceuticals by combining group strengths

TAIHO ONCOLOGY, INC.

In 2002, Taiho Pharmaceutical established the U.S. subsidiary Taiho Oncology, Inc., to provide direct management of research and development programs for obtaining marketing approval of anticancer drugs in the U.S. and European markets. The selected professional team works together with medical professionals and organizations in the U.S. and Europe, while cooperating with Taiho Pharmaceutical staff in Japan, to advance the global development of new drugs that can contribute to cancer treatment. As a direct result of these efforts, the New Drug Application for a new anticancer drug TAS-102 (brand name in Japan, "Lonsurf") is under review by the FDA and preparations for the anticipated first commercial product launch in the U.S. are nearly complete.

Company Overview

Company Name TAIHO ONCOLOGY, INC.
Established August 8, 2002
Representative Eric Benn, President & CEO
Business Research and development of anticancer drugs
Head office 202 Carnegie Center, Princeton,
New Jersey 08540 USA
Tel: +1-609-750-5300
Fax: +1-609-750-7450

* Please click the link below to see Taiho's latest product pipeline information.

http://taiho.co.jp/english/rd/pipeline.html

TAIHO PHARMA EUROPE, LTD.

Taiho Pharma Europe, Ltd. (TPEL), located in Uxbridge, UK, was established in February 2009 as a subsidiary of Taiho Pharmaceutical Co., Ltd. Working closely with the professional R&D teams in Japan and the US, TPEL provides direct management of research and development programs and regulatory affairs support toward obtaining marketing approval of anticancer drugs in the European markets.

Company Overview

Company Name TAIHO PHARMA EUROPE, LTD.
Established February 11, 2009
Representative Eric Benn, Director
Business Research and development of anticancer drugs
Head office 1 Furzeground Way, Stockley Park, Uxbridge, UB11 1BD UK
Tel: +44 (0)208 622 3294

TAIHO PHARMACEUTICAL OF BEIJING CO., LTD.

In August 2008, Taiho Pharmaceutical established the Chinese subsidiary, Taiho Pharmaceutical of Beijing Co., Ltd. Taiho Beijing conducts clinical development to obtain approval from authorities in China on anticancer agents researched and developed by Taiho Pharmaceutical, and it provides information to Chinese oncologists. In July 2009, the company put TS-1 on the market and is currently developing its business mainly in China's coastal areas. Aiming to gain broad recognition of Taiho among the Chinese people as a specialty pharma leader in anticancer agents, the company is contributing to cancer treatment in China by providing oncologists, other medical care professionals, and patients with effective drugs to support them in the battle against cancer.

Company Overview

Company Name Taiho Pharmaceutical of Beijing Co., Ltd.
Established August 8, 2008
Representative Shingo Seki, General Manager
Business Providing information on pharmaceuticals and clinical development work
Head office 9F-9A3, Hanwei Plaza, 7th,
Guanghua Rd., Chaoyang Dist.,
Beijing City 100004 China
Tel: +86-5971-4220
Fax: +86-5971-4221

TAIHO PHARMA SINGAPORE PTE. LTD.

Taiho Pharma Singapore Pte. Ltd. was established in Singapore in August 2011 as a subsidiary of Taiho Pharmaceutical Co., Ltd. Sticking with our philosophy “by local, for local,” Taiho Pharma Singapore covers a wide range of jobs such as clinical research, regulatory affairs, medical affairs and sales as a hub for Taiho's oncology business in South East Asia in close touch with local medical oncologists and the other medical professionals in cancer care. Taiho Pharma Singapore hopes to share our smile and happiness with local cancer patients, medical oncologists and the other medical professionals in cancer care in South East Asia by introducing our anticancer drugs and data with high quality.

Company Overview

Company Name Taiho Pharma Singapore Pte. Ltd.
Established August 8, 2011
Representative Yoshimasa Nishimura, Managing Director
Business Import/export, sales and marketing of pharmaceuticals, and clinical development
Head office 390 Havelock Road #06-07, King's
Centre 169662 Singapore
Tel: +65-6887-5104
Fax: +65-6887-3253

Top of Page